Journavx (generic name: suzetrigine) is a newly approved non-opioid analgesic developed by Vertex Pharmaceuticals for the treatment of moderate to severe acute pain in adults. The U.S. Food and Drug Administration (FDA) granted its approval on January 30, 2025. The NEW non-narcotic pain reliever has been press released around the globe in wake of a ten year opioid crisis. At the same time, the Center For Disease Control (CDC) provisionally reported that opioid-related overdose deaths decreased by 17% in 2024. That said, here’s what we know about this pain medication:
How Does Journavx Work?
Journavx operates by selectively inhibiting the NaV1.8 sodium channels located on pain-sensing nerve cells in the peripheral nervous system. By blocking these channels, the drug prevents pain signals from reaching the brain, offering pain relief without the addictive potential associated with opioids.
Journavx Clinical Efficacy
The FDA’s approval was based on two randomized, double-blind, placebo- and active-controlled clinical trials involving patients undergoing abdominoplasty and bunionectomy surgeries. Participants receiving Journavx reported a statistically significant reduction in pain compared to those given a placebo.
Is Suzetrigine Safe?
Common side effects observed in clinical trials included itching, muscle spasms, elevated blood levels of creatine phosphokinase, and rash. Journavx is contraindicated for use with strong CYP3A inhibitors, and patients are advised to avoid consuming grapefruit products during treatment. Most importantly, talk to your pain management doctor and discuss all medications you are taking along with medical history.
Dosage and Administration
The recommended initial dose of suzetrigine is 100 mg taken on an empty stomach (either 1 hour before or 2 hours after eating). Subsequently, a maintenance dose of 50 mg is administered every 12 hours, starting 12 hours after the initial dose. Dosage adjustments may be necessary for patients with liver impairment or those taking medications that interact with Journavx.
Pain Management Impact
Following the FDA’s approval, Vertex Pharmaceuticals’ stock experienced an 8% increase. This reflected investor optimism about the drug’s potential in the pain management market. Journavx represents a significant advancement in pain management. At the same time, the non-narcotic pain reliver (may) offer an effective alternative to opioids without the associated risks of addiction.
About Celadon Recovery
Celadon is comprehensive addiction and mental health treatment center located along the shores of the Caloosahatchee River in Fort Myers, Florida. With a full-continuum of care including detox, residential, and outpatient programs, we are committed to quality substance use and co-occurring disorder care. Call us today at 239-266-2141.
